MM Treatment: Clinical Advice on the Care of Patients Receiving Talquetamab

Opinion
Video

Tiffany Richards, PhD, ANP-BC, and the rest of the panel offer clinical advice on the care of patients with multiple myeloma who are receiving talquetamab.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
Data from the AQUILA trial support early intervention with fixed-duration subcutaneous daratumumab for those with high-risk smoldering multiple myeloma.

Subcutaneous Daratumumab Improves PFS in Smoldering Multiple Myeloma

Russ Conroy
September 9th 2025
Article
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
September 9th 2025
Podcast
The safety profile of carfilzomib, lenalidomide, and dexamethasone was tolerable in fit patients with newly diagnosed multiple myeloma.

Weekly Carfilzomib Combination Shows MRD Negativity in Multiple Myeloma

Roman Fabbricatore
September 9th 2025
Article
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
September 9th 2025
Podcast
Therapy with anti-CD38 monoclonal antibodies significantly increased the minimal residual disease–negative rate.

Further Research on Anti-CD38 mAbs Warranted in Multiple Myeloma

Tim Cortese
September 9th 2025
Article
Phase 3 findings may contribute to the selection of triplet or quadruplet therapies in newly diagnosed multiple myeloma via frailty-based assessments.

Carfilzomib Regimens Improve MRD Outcomes in Older, Fit NDMM Population

Russ Conroy
September 9th 2025
Article